Valeant to sell filler, toxin rights to Nestle

Valeant Pharmaceuticals has agreed to sell all rights to Restylane, Perlane, Emervel, Sculptra and Dysport, all currently owned or held by Valeant, to Nestle S.A. for $1.4 billion in cash, according to a press release.Nestle expects to operate the acquired assets through Galderma S.A, with completed acquisition anticipated in July, the release stated.

Full Story →